Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study
Open Access
- 1 January 2020
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 9 (1), e15687
- https://doi.org/10.2196/15687
Abstract
Background: Standard surgical treatments for lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) use a transurethral approach. Drawbacks are the need for general or spinal anesthesia and complications such as hematuria, strictures, and cloth retention. Therefore, a minimal invasive technique under local anesthesia is desired to improve patient safety. Recently, SoracteLite transperineal laser ablation (TPLA) has been introduced as a novel minimal invasive treatment for BPO. The system used is unique because 4 laser sources are independently available. This 1064-nm diode laser induces coagulative necrosis. Moreover, TPLA is unique because it has a transperineal approach and can be performed under local anesthesia in an outpatient setting. Objective: The primary objective of this study is to determine the safety and feasibility of TPLA treatment for men, who are fit for standard surgery, with LUTS due to BPO. The secondary objectives are to determine functional outcomes by flowmetry and patient-reported outcome measures (PROMs), side effects, and tissue changes observed on imaging. Methods: This study is a prospective, single center, interventional pilot study IDEAL framework stage 2a and will include 20 patients. Eligible patients are men >= 40 years of age, with a prostate volume of 30 to 120 cc, have urodynamically proven bladder outlet obstruction, and have a peak urinary flow of 5 to 15 mL per second. All patients will undergo TPLA of their prostate under local anesthesia by using the EchoLaser system. Depending on the prostate volume, 2 to 4 laser fibers will be placed bilaterally into the prostate. Patient follow-up consists of uroflowmetry, PROMs, and imaging by using contrast-enhanced ultrasound. Total follow-up is 12 months following treatment. Results: Presently, recruitment of patients is ongoing. Publication of first results is expected by early 2020. Conclusions: TPLA offers the potential to be a novel minimal invasive technique for treatment of LUTS due to BPO in men fit for standard desobstruction. This study will evaluate the safety and feasibility of TPLA and report on functional outcomes and tissue changes observed on imaging following TPLA treatment.This publication has 23 references indexed in Scilit:
- Aquablation – image‐guided robot‐assisted waterjet ablation of the prostate: initial clinical experienceBJU International, 2015
- Efficacy and Safety of Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaUrology, 2015
- MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomyEuropean Radiology, 2015
- EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic ObstructionEuropean Urology, 2015
- Hematuria Grading Scale: A New Tool for Gross HematuriaUrology, 2013
- Image Guided Photothermal Focal Therapy for Localized Prostate Cancer: Phase I TrialJournal of Urology, 2009
- Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic HyperplasiaBMC Urology, 2006
- Interstitial Laser Coagulation Treatment of Benign Prostatic Hyperplasia: Is It to Be Recommended?Journal of Endourology, 2003
- Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up StudyUrology, 2002
- Interstitial laser coagulation in the treatment of benign prostatic hyperplasia using a diode laser system: results of an evolving technologyProstate Cancer and Prostatic Diseases, 1999